Daewon Pharmaceutical Co., Ltd.

KOSE:A003220 Stock Report

Market Cap: ₩303.9b

Daewon Pharmaceutical Future Growth

Future criteria checks 4/6

Daewon Pharmaceutical is forecast to grow earnings and revenue by 45.8% and 9.4% per annum respectively. EPS is expected to grow by 44.8% per annum. Return on equity is forecast to be 12% in 3 years.

Key information

45.8%

Earnings growth rate

44.8%

EPS growth rate

Pharmaceuticals earnings growth30.1%
Revenue growth rate9.4%
Future return on equity12.0%
Analyst coverage

Low

Last updated08 Jan 2025

Recent future growth updates

Recent updates

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) P/E Still Appears To Be Reasonable

Jan 06
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) P/E Still Appears To Be Reasonable

Daewon Pharmaceutical's (KRX:003220) Conservative Accounting Might Explain Soft Earnings

Nov 22
Daewon Pharmaceutical's (KRX:003220) Conservative Accounting Might Explain Soft Earnings

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Aug 13
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

Jul 17
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) 27% Jump Shows Its Popularity With Investors

There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

Mar 21
There May Be Reason For Hope In Daewon Pharmaceutical's (KRX:003220) Disappointing Earnings

Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Mar 26
Does Daewon Pharmaceutical (KRX:003220) Have A Healthy Balance Sheet?

Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?

Mar 07
Is Daewon Pharmaceutical Co., Ltd. (KRX:003220) A Smart Pick For Income Investors?

Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?

Feb 18
Do Insiders Own Lots Of Shares In Daewon Pharmaceutical Co., Ltd. (KRX:003220)?

Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Jan 31
Daewon Pharmaceutical Co., Ltd.'s (KRX:003220) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?

Jan 13
Did You Miss Daewon Pharmaceutical's (KRX:003220) 26% Share Price Gain?

Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend

Dec 24
Here's What We Like About Daewon Pharmaceutical's (KRX:003220) Upcoming Dividend

Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly

Dec 10
Daewon Pharmaceutical (KRX:003220) Seems To Use Debt Quite Sensibly

Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?

Nov 22
Does Daewon Pharmaceutical Co., Ltd. (KRX:003220) Have A Place In Your Dividend Portfolio?

Earnings and Revenue Growth Forecasts

KOSE:A003220 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026728,30047,60014,20065,4001
12/31/2025667,30043,40010,80059,8001
12/31/2024602,60021,100-52,500-9001
9/30/2024593,94516,019-23,10323,974N/A
6/30/2024566,09414,688-27,4393,232N/A
3/31/2024561,16423,53413,48935,232N/A
12/31/2023526,95223,91731,12451,734N/A
9/30/2023508,63426,1332,41117,105N/A
6/30/2023501,89931,74918,27330,359N/A
3/31/2023485,91731,07112,26727,176N/A
12/31/2022478,88531,94413,04826,413N/A
9/30/2022457,30834,72832,45247,937N/A
6/30/2022425,58829,92829,07043,137N/A
3/31/2022396,23925,57526,64537,726N/A
12/31/2021354,1766,98910,70722,413N/A
9/30/2021330,6863,431-1,0729,864N/A
6/30/2021315,870657-2,21910,266N/A
3/31/2021302,8892,120-5,1969,803N/A
12/31/2020308,50117,6409,56724,951N/A
9/30/2020318,29724,07317,18632,837N/A
6/30/2020318,09127,0379,73827,081N/A
3/31/2020322,12428,9043,49725,727N/A
12/31/2019317,82827,289-5,68130,971N/A
9/30/2019310,80225,085-11,69737,498N/A
6/30/2019299,87123,773-14,58438,140N/A
3/31/2019291,78522,795-16,33532,324N/A
12/31/2018286,65323,744-2,55040,032N/A
9/30/2018279,33818,195-9,54024,814N/A
6/30/2018279,93321,779N/A23,703N/A
3/31/2018273,78414,212N/A22,066N/A
12/31/2017265,46210,742N/A4,265N/A
9/30/2017258,27514,662N/A14,033N/A
6/30/2017248,35013,180N/A12,924N/A
3/31/2017245,49019,632N/A21,123N/A
12/31/2016240,72220,242N/A20,792N/A
9/30/2016235,04620,787N/A19,544N/A
6/30/2016229,69116,712N/A19,899N/A
3/31/2016222,26717,791N/A19,164N/A
12/31/2015216,18717,695N/A25,817N/A
9/30/2015208,27017,453N/A25,040N/A
6/30/2015201,66919,596N/A25,604N/A
3/31/2015190,87017,286N/A21,799N/A
12/31/2014181,98515,729N/A17,447N/A
9/30/2014174,30914,143N/A12,782N/A
6/30/2014168,94011,977N/A12,571N/A
3/31/2014165,71712,625N/A15,754N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: A003220's forecast earnings growth (45.8% per year) is above the savings rate (2.7%).

Earnings vs Market: A003220's earnings (45.8% per year) are forecast to grow faster than the KR market (25.9% per year).

High Growth Earnings: A003220's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A003220's revenue (9.4% per year) is forecast to grow faster than the KR market (8.9% per year).

High Growth Revenue: A003220's revenue (9.4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: A003220's Return on Equity is forecast to be low in 3 years time (12%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/15 02:08
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Daewon Pharmaceutical Co., Ltd. is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jisoo LeeDAOL Investment & Securities Co., Ltd.
Jae Hoon ShinHanwha Investment & Securities Co., Ltd.
Changhee WooIBK Securities Co. Ltd.